Incyte

Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.

Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For more information, visit Incyte.com and follow @Incyte

PharmaEssentia

PharmaEssentia is a global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia, hepatitis, and other diseases. PharmaEssentia is developing ropeginterferon alfa-2b, a novel, long-acting, mono-pegylated proline interferon for both PV and ET. It is uniquely administered once every two weeks, offering improved tolerability and convenience, and may offer the potential for disease modification. A Phase III clinical trial for ropeginterferon alfa-2b in PV was recently completed, and the company plans to present data to the U.S. FDA for approval. If approved, ropeginterferon alfa-2b is expected to be the first interferon approved for PV worldwide and the only approved first-line treatment for PV in the U.S.http://www.pharmaessentia.com/ or http://www.ropeginf.com/

New trial evaluating ropeginterferon alfa-2b to treat ET

Sobi

Sobi is a biopharmaceutical company that has the FDA-approved drug VONJO. VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Sobi.com

GSK

GSK is a global biopharma company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. GSK’s lead drug candidate, momelotinib, is an orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor. More than 1,200 subjects have received momelotinib in clinical trials, where it has demonstrated a potentially differentiated therapeutic profile in myelofibrosis. GSK is running the MOMENTUM Phase 3 clinical trial, a randomized double-blind trial designed to enroll 180 myelofibrosis patients previously treated with a JAK inhibitor. Momelotinib will be evaluated on endpoints including constitutional symptoms, anemia benefits (including eliminating or reducing the need for frequent blood transfusions), and spleen control. Dr. Srdan Verstovsek, The University of Texas MD Anderson Cancer Center, is Chief Investigator of the MOMENTUM trial. The FDA has granted momelotinib Fast Track designation, learn more.

GSK.com

Disc Medicine

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. Disc Medicine is building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. DISC-0974 is a first-in-class monoclonal antibody (mAB) against hemojuvelin (HJV) to suppress the production of hepcidin and enhance iron levels to treat anemia of inflammation. DISC-3405 is a mAb that inhibits TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) to induce endogenous expression of hepcidin. By increasing hepcidin levels to reduce iron levels, DISC-3405 has the potential to address a wide range of hematologic diseases.

www.discmedicine.com

Merck

Merck is developing and evaluating the enzyme lysine-specific demethylase 1 (LSD1), Bomedemstat. LSD1 is an epigenetic regulator of gene expression critical for regulating myelopoiesis. Inhibition of LSD1 had profound effects on the natural history of myelofibrosis and essential thrombocythemia in mouse models of those diseases. To learn more, please www.merck.com

Kartos Therapeutics

Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington. We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team. Together, we’re building an exciting biotechnology company with a culture defined by caring, ambition, dedication, and teamwork!

kartosthera.com

Karyopharm

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Our primary focus is on developing novel drugs that we hope will help treat patients with certain blood cancers or solid tumor malignancies.

Karyopharm Therapeutics is investigating the safety and efficacy of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve patients with myelofibrosis.

Protagonist Therapeutics

Protagonist leverages its proprietary peptide technology platform to discover and develop novel drug candidates that can transform the existing treatment paradigms in diseases with significant unmet medical needs.

PTG-300 is a mimetic of the natural hormone hepcidin that is currently in a phase 2 study in polycythemia vera (PV), a rare blood disorder, and a phase 2 study in hereditary hemochromatosis (HH), a blood disorder arising from absence or deficiency of hepcidin gene. Hepcidin is a master regulator of iron homeostasis and controls the absorption, storage, and distribution of iron in the body.

protagonist-inc.com

Silence Therapeutics

www.silence-therapeutics.com

At Silence, we aim to transform peoples’ lives around the world by silencing diseases through our precision-engineered medicines and driving positive change for the communities around us. One area we’re working on developing a potential gene silencing therapy for is Polycythemia Vera (PV). Look out for further information about our study launched at the start of 2023 in the US (and beyond).